Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XW4W
|
|||
| Former ID |
DIB005862
|
|||
| Drug Name |
SEP-227900
|
|||
| Indication | Cognitive impairment [ICD-11: 6D71; ICD-10: F06.7] | Terminated | [1] | |
| Company |
Sunovion Pharmaceuticals Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | D-amino acid oxidase (DAO) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Arginine and proline metabolism | ||||
| D-Arginine and D-ornithine metabolism | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Peroxisome | ||||
| Pathwhiz Pathway | Arginine and Proline Metabolism | |||
| D-Arginine and D-Ornithine Metabolism | ||||
| WikiPathways | Metabolism of amino acids and derivatives | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors. Open Med Chem J. 2010; 4: 3-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.